Lorena Fontan Gabas

Title: Innovator in Cancer Research: Lorena Fontan Gabas

Introduction: Lorena Fontan Gabas is a notable inventor based in New York, NY, recognized for her significant contributions to cancer research. With a portfolio of three patents, she focuses on developing compounds that impact the treatment of various malignancies, particularly those associated with MALT1 protein activities.

Latest Patents: Her latest patents include "Inhibitors of MALT1 and uses thereof," which detail compounds that inhibit the MALT1 protein, responsible for sustaining NF-κB signaling in specific cancers, such as activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL). She also holds a patent for "MALT1 inhibitors and uses thereof," which outlines pharmaceutical compositions useful as MALT1 inhibitors and their application in treating proliferative disorders, including different types of cancers, benign neoplasms, and autoimmune diseases.

Career Highlights: Lorena has worked with leading research institutions, including Cornell University and the Dana-Farber Cancer Institute Inc. Her research has contributed to the understanding and potential treatment of MALT1-related diseases, showcasing her commitment to advancing cancer therapeutics.

Collaborations: Throughout her career, she has collaborated with esteemed colleagues, including Nathanael Schiander Gray and David A. Scott, further enhancing her innovative work and broadening the impact of her research within the scientific community.

Conclusion: Lorena Fontan Gabas exemplifies the spirit of innovation within the field of cancer research. Through her patents and collaborative efforts, she continues to contribute valuable insights and solutions in the fight against cancer, paving the way for future advancements in medical treatments.